Laboratory of Genetics and Molecular Hematology, University of Sao Paulo Medical School (HCFMUSP), Sao Paulo, Brazil.
Clin Chem Lab Med. 2013 Feb;51(2):371-8. doi: 10.1515/cclm-2012-0225.
Antibodies against low-density lipoproteins (LDLs) that have been oxidized are associated with development of atherosclerotic lesions. In individuals infected with human immunodeficiency virus type 1 (HIV-1) with or without therapy, dyslipidemia and increased cardiovascular risk are observed.
Serum levels of IgG antibodies against oxidized LDLs (IgG anti-oxLDL Abs) were determined by assay in 151 HIV-1-infected patients. Of these, 42 patients did not receive anti-retroviral therapy (ART-naïve), whereas 109 received highly active anti-retroviral therapy (HAART) consisting of lopinavir/ritonavir (LOP/r; n=50), efavirenz (EFV; n=30) and nevirapine (NVP; n=29) associated with nucleoside reverse transcriptase inhibitors. HIV-1 seronegative individuals (n=43) participated in the study. The following parameters were quantified: total cholesterol and its fractions, atherogenic indices (AIs), apolipoproteins A1 and B100, high sensitivity C-reactive protein, CD4+ and CD8+ T cells, and HIV-1-RNA.
Levels of IgG anti-oxLDL Abs were significantly higher (p<0.05) in the LOP/r group compared with the EFV and/or NVP and the seronegative group: median 0.32 (0.15, 0.58; 95% confidence interval) vs. 0.25 (0.13, 0.53) vs. 0.18 (0.04, 0.38), respectively. HIV-1-infected ART-naïve patients (n=42) presented antibodies levels similar to those observed for the LOP/r group, 0.33 (0.13, 0.63; p>0.05). The levels of IgG anti-oxLDL Abs correlated with an increase in AIs (r=0.216; p=0.036) and triglycerides (r=0.220; p=0.044) in the LOP/r group, and AIs in the ART-naïve group (r=0.300; p=0.046).
Patients treated with LOP/r showed higher levels of IgG anti-oxLDL Abs compared with patients treated with EFV or NVP regimens, and these levels were associated with an increase in AIs.
针对已氧化的低密度脂蛋白（LDLs）的抗体与动脉粥样硬化病变的发展有关。在感染人类免疫缺陷病毒 1 型（HIV-1）的个体中，无论是否接受治疗，均可观察到血脂异常和心血管风险增加。
通过检测，在 151 例 HIV-1 感染患者中确定了针对氧化型 LDL（IgG 抗 oxLDL Abs）的 IgG 抗体血清水平。其中，42 例患者未接受抗逆转录病毒治疗（ART-初治），而 109 例患者接受了由洛匹那韦/利托那韦（LOP/r；n=50）、依非韦伦（EFV；n=30）和奈韦拉平（NVP；n=29）组成的高效抗逆转录病毒治疗（HAART），并联合使用核苷逆转录酶抑制剂。43 名 HIV-1 阴性个体参与了该研究。对以下参数进行了量化：总胆固醇及其各成分、致动脉粥样硬化指数（AIs）、载脂蛋白 A1 和 B100、高敏 C 反应蛋白、CD4+和 CD8+T 细胞以及 HIV-1-RNA。
与 EFV 和/或 NVP 组和阴性组相比，LOP/r 组 IgG 抗 oxLDL Abs 水平显著升高（p<0.05）：中位数 0.32（0.15，0.58；95%置信区间）比 0.25（0.13，0.53）比 0.18（0.04，0.38）。HIV-1 感染的初治患者（n=42）的抗体水平与 LOP/r 组观察到的水平相似，为 0.33（0.13，0.63；p>0.05）。LOP/r 组 IgG 抗 oxLDL Abs 水平与 AIs（r=0.216；p=0.036）和甘油三酯（r=0.220；p=0.044）的增加相关，与初治组的 AIs 相关（r=0.300；p=0.046）。
与接受 EFV 或 NVP 方案治疗的患者相比，接受 LOP/r 治疗的患者 IgG 抗 oxLDL Abs 水平更高，这些水平与 AIs 的增加有关。
